713-85-9

Basic information

• Product Name: 3'-fluoro-4'-methoxycinnamic acid
• Synonyms: 3-(3-Fluoro-4-methoxyphenyl)propenoic acid;Einecs 211-931-9;3-(3-Fluoro-4-methoxyphenyl)acrylic acid;3-(3-Fluoro-4-methoxyphenyl)-2-propenoic acid
• CAS NO: 713-85-9
• Molecular Formula: C₁₀H₉FO₃
• Molecular Weight: 196.18
• EINECS: 211-931-9
• Mol File: 713-85-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3'-fluoro-4'-methoxycinnamic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-fluoro-4'-methoxycinnamic acid(713-85-9)
• EPA Substance Registry System: 3'-fluoro-4'-methoxycinnamic acid(713-85-9)

Safety Data

• Hazardous Substances Data: 713-85-9(Hazardous Substances Data)

Usage

General Description

3'-fluoro-4'-methoxycinnamic acid is a chemical compound with the molecular formula C11H9FO3. It is a derivative of cinnamic acid, a naturally occurring compound found in plants. The presence of a fluoro and methoxy group on the cinnamic acid structure gives it unique chemical properties and potential applications in pharmaceutical and organic chemical synthesis. Studies have shown that 3'-fluoro-4'-methoxycinnamic acid exhibits anti-inflammatory and antioxidant properties, making it a potential candidate for drug development. Additionally, its chemical structure makes it suitable for use as a building block in the synthesis of various compounds, particularly in the development of new drugs and pharmaceuticals.

Upstream product

• 141-82-2 malonic acid 
• 351-54-2 3-fluoro-p-anisaldehyde 

Downstream Products

• 69888-90-0 3-(3-fluoro-4-methoxyphenyl)propionic acid 
• 848349-23-5 3-(3-fluoro-4-methoxyphenyl)propan-1-ol 
• 83802-71-5 5-fluoro-6-methoxy-2,3-dihydro-1H-inden-1-one 

Relevant articles and documents

Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate

The acetylcholinesterase (AChE) inhibitors remain key therapeutic drugs for the treatment of Alzheimer's disease (AD). However, the low-safety window limits their maximum therapeutic benefits. Here, a novel kinetics-driven drug design strategy was employed to discover new-generation AChE inhibitors that possess a longer drug-target residence time and exhibit a larger safety window. After detailed investigations, compound 12 was identified as a highly potent, highly selective, orally bioavailable, and brain preferentially distributed AChE inhibitor. Moreover, it significantly ameliorated cognitive impairments in different mouse models with a lower effective dose than donepezil. The X-ray structure of the cocrystal complex provided a precise binding mode between 12 and AChE. Besides, the data from the phase I trials demonstrated that 12 had good safety, tolerance, and pharmacokinetic profiles at all preset doses in healthy volunteers, providing a solid basis for its further investigation in phase II trials for the treatment of AD.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.